DURHAM, NORTH CAROLINA – 6 June 2022 – Today, Carocell Bio, the anti-inflammation company revolutionising the treatment of inflammatory diseases with its peptide-based approach to mitogen-activated protein kinase inhibition (MAPKi), announced that it had been selected to pitch to investors at the Redefining Early Stage Investments (RESI) Digital Innovator’s Pitch Challenge. The pitching event, taking place during its online conference (7-9 June 2022), is specifically focused on connecting early-stage companies and products with capital and channel partners.
Mike Davies, CEO, Carocell Bio will be pitching online at 10 am EDT / 3 pm BST on Tuesday, 7 June, 2022. Click here to register and attend online.
RESI helps life sciences and healthcare companies find partners that best fit their technology and stage of development. It is cross-border and cross-domain, and connects companies across ten categories of global investors including drugs, devices, diagnostics and digital health.
Last month, Carocell Bio announced that it had received approval from the UK’s Health Research Authority (HRA) to test its lead candidate proprietary peptide JEL3108 in human burns and reconstructive surgery tissue samples. This is to investigate Carocell Bio’s anti-inflammation approach to treating severe burns and preventing scar formation after surgery, based upon proprietary peptides that target the body’s intracellular inflammation cascade via MAPKi. MAPK is a pivotal enzyme in pathways critical to the body’s inflammatory response. Although previous systemic MAPKi have failed for safety reasons, they have demonstrated clinical efficacy. Carocell Bio’s peptide-based approach could potentially deliver safer and novel therapeutic options for patients.
Last year, the company announced it had received over USD $125,000 (almost GBP £100,000) in additional funding from Innovate UK to study the effect of the peptides in burns, and received USD $500,000 (GBP £400,000) seed investment from Deepbridge Capital.